KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Invested Capital (2019 - 2025)

Historic Invested Capital for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $18.7 billion.

  • Royalty Pharma's Invested Capital rose 396.03% to $18.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $18.7 billion, marking a year-over-year increase of 396.03%. This contributed to the annual value of $18.7 billion for FY2025, which is 396.03% up from last year.
  • As of Q4 2025, Royalty Pharma's Invested Capital stood at $18.7 billion, which was up 396.03% from $18.6 billion recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Invested Capital ranged from a high of $18.7 billion in Q4 2025 and a low of $15.7 billion during Q1 2021
  • For the 5-year period, Royalty Pharma's Invested Capital averaged around $17.1 billion, with its median value being $17.3 billion (2021).
  • As far as peak fluctuations go, Royalty Pharma's Invested Capital surged by 11860.64% in 2021, and later tumbled by 1033.44% in 2023.
  • Over the past 5 years, Royalty Pharma's Invested Capital (Quarter) stood at $17.3 billion in 2021, then fell by 4.05% to $16.6 billion in 2022, then fell by 2.54% to $16.2 billion in 2023, then rose by 10.7% to $18.0 billion in 2024, then increased by 3.96% to $18.7 billion in 2025.
  • Its Invested Capital was $18.7 billion in Q4 2025, compared to $18.6 billion in Q3 2025 and $17.5 billion in Q2 2025.